Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group
Published Online: 24 FEB 2014
Assessed as up-to-date: 6 FEB 2014
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Sinha IP, Southern KW, Dwan K, Patel S. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010966. DOI: 10.1002/14651858.CD010966.
- Publication Status: New
- Published Online: 24 FEB 2014
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the effects of CFTR correctors on clinically important outcomes in children and adults with CF. The clinically important outcomes will include both benefits and harms that participants may experience.